Evogene (EVGN) EBT Margin (2012 - 2026)
Evogene (EVGN) posted EBT Margin of 1768.26% for Q1 2026, down 4.02% sequentially from 1700.0% in Q4 2025, and down 168704.0% YoY from N/an in Q1 2025.
Evogene (EVGN) EBT Margin (2012 - 2026) Analysis & Trends
Evogene has reported EBT Margin for 15 years, with the latest figure at 1768.26% in Q1 2026.
- Quarterly EBT Margin fell 168704.0% year-over-year to 1768.26% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 949.02% (down 75304.0% YoY) and the FY2025 annual result came in at 350.32%, down 8481.0% from the prior year.
- EBT Margin eased to 1768.26% in Q1 2026 per EVGN's latest filing, from 1700.0% in the prior quarter.
- Over five years, EBT Margin peaked at 64.16% in Q4 2024 and troughed at 3841.35% in Q1 2022.
- A 5-year average of 1100.54% and a median of 874.36% in 2025 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2022 and 2025: EBT Margin jumped 398382 bps in 2022, then sank 176416 bps in 2025.
- Over 5 years, EBT Margin stood at 572.12% in 2022, then slumped by 122 bps to 1270.07% in 2023, then soared by 105 bps to 64.16% in 2024, then tumbled by 2750 bps to 1700.0% in 2025, then retreated by 4 bps to 1768.26% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 1768.26%, 1700.0%, and 874.36% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 13.77% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -25.06% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -2.67% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 12.09% |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 | -1,768.26% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,768.26% |
| Dec 31, 2025 | -1,700.00% |
| Sep 30, 2025 | -874.36% |
| Jun 30, 2025 | -399.10% |
| Mar 31, 2025 | -81.22% |
| Dec 31, 2024 | 64.16% |
| Sep 30, 2024 | -387.76% |
| Jun 30, 2024 | -752.40% |
| Mar 31, 2024 | -91.77% |
| Dec 31, 2023 | -1,270.07% |
| Sep 30, 2023 | -102.55% |
| Jun 30, 2023 | -1,186.09% |
| Mar 31, 2023 | -1,096.10% |
| Dec 31, 2022 | -572.12% |
| Sep 30, 2022 | -1,536.05% |
| Jun 30, 2022 | -3,114.10% |
| Mar 31, 2022 | -3,841.35% |
| Dec 31, 2021 | -2,601.29% |
| Sep 30, 2021 | -5,519.87% |
| Jun 30, 2021 | -5,107.41% |